You are here

NIH Study To Measure How Rheumatoid Arthritis Patients Rate Improvement Change

BETHESDA, MD -- August 4, 2004 -- A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health. The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.

The Clinically Important Changes in Rheumatoid Arthritis study will recruit 300 people 18 years of age or older who have been diagnosed with RA. Researchers are particularly interested in patients who are currently being treated with prednisone, methotrexate, leflunomide, infliximab or etanercept.

Patients will be evaluated twice at the NIH Clinical Center in Bethesda, Maryland: once at the start of the study and again over a 1- to 4-month period. At each visit, patients will undergo assessments, including a physical exam, a grip strength test, a walking test and a blood test. They will complete a computer-based exercise, and answer written questionnaires.

The questionnaires will ask patients to rate the importance of change in pain, morning stiffness, fatigue, joint swelling, functioning, worry, depression and overall impressions since the first visit.

Many people with RA complain about the daily joint pain that is associated with the disease. In addition, doctors have noted that patients have feelings of helplessness, depression and anxiety. These symptoms together can interfere with a person's ability to carry out normal daily activities.

Generally, doctors evaluate patients' health and treatment based on measures such as the number of joints that are tender or swollen, morning stiffness, grip strength and pain severity. Less attention is given to whether treatment results are meaningful to patients.

The results of this study will give doctors a measure of the degree of improvements in symptoms and signs of arthritis that patients think are important. This will provide a target to be used in evaluating new treatments. Using these patient-based criteria, doctors will know if a new treatment has a high likelihood of being rated by patients as helpful or not.

Rheumatoid arthritis is an autoimmune disease that affects 2.1 million Americans, occurring two to three times more often in women than in men. RA typically affects many joints and is a chronic ongoing illness, requiring long periods of observation and management. It is characterized by inflammation of the membrane lining the joint, which causes pain, stiffness, warmth, redness and swelling. The inflamed joint lining, the synovium, can invade and damage bone and cartilage.

For additional information on the RA clinical trial, please contact:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: (301) 594-9774 (local), 1-866-411-1010 (toll free)
or e-mail at prpl@cc.nih.gov

Source: The National Intitutes of Health

Recent Headlines

Roche Drug Outperformed Standard of Care in Phase 2 Study
U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs